Larry Trittschuh - Healthequity Executive Vice President Chief Security Officer

HQY -  USA Stock  

USD 62.80  1.82  2.98%

  President
Mr. Larry Trittschuh is Executive Vice President, Chief Security Officer of the Company. Mr. Trittschuh will join HealthEquity from his current position as CSO for Barclays Americas. Mr. Trittschuh was Senior Vice President, Information Security for Synchrony Financial prior to joining Barclays, and was Executive Director, Threat Management Deputy Chief Information Security Officer for General Electric prior to that. Mr. Trittschuh has more than 25 years of experience including service in the USAF
  President Since 2018      
801 727 1000  https://www.healthequity.com
Trittschuh holds a BS from the USAF Academy.

Larry Trittschuh Latest Insider Activity

Tracking and analyzing the buying and selling activities of Larry Trittschuh against Healthequity stock is an integral part of due diligence when investing in Healthequity. Larry Trittschuh insider activity provides valuable insight into whether Healthequity is net buyers or sellers over its current business cycle. Note, Healthequity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Healthequity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Healthequity Management Efficiency

Healthequity has Return on Asset of 0.87 % which means that on every $100 spent on asset, it made $0.87 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (2.74) %, meaning that it generated no profit with money invested by stockholders. Healthequity management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to rise to 1.74 in 2022, whereas Return on Average Assets are likely to drop (0.0144)  in 2022. Healthequity Total Assets are fairly stable at the moment as compared to the past year. Healthequity reported Total Assets of 3.11 Billion in 2021. Assets Non Current is likely to rise to about 3 B in 2022, whereas Current Assets are likely to drop slightly above 316.7 M in 2022.
The company has 1.01 B in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. Healthequity has a current ratio of 2.24, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Healthequity until it has trouble settling it off, either with new capital or with free cash flow. So, Healthequity's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Healthequity sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Healthequity to invest in growth at high rates of return. When we think about Healthequity's use of debt, we should always consider it together with cash and equity.
Is Healthequity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Healthequity. If investors know Healthequity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Healthequity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Healthequity is measured differently than its book value, which is the value of Healthequity that is recorded on the company's balance sheet. Investors also form their own opinion of Healthequity's value that differs from its market value or its book value, called intrinsic value, which is Healthequity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Healthequity's market value can be influenced by many factors that don't directly affect Healthequity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine Healthequity value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 11 records

PRESIDENT Since

Seth FrankAllscripts Hlthcare
N/A
Julie WilsonCerner Corp
2013
Kevin BurnsIcad Inc
2015
Zane BurkeCerner Corp
N/A
Scott AregladoIcad Inc
2019
Melinda WhittingtonAllscripts Hlthcare
2016
Julia WilsonCerner Corp
2013
Richard ChristopherIcad Inc
2016
Allan KellsCerner Corp
N/A
Randy SimsCerner Corp
2011
Alan FowlesAllscripts Hlthcare
2017
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company was incorporated in 2002 and is headquartered in Draper, Utah. Healthequity operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 3688 people. Healthequity (HQY) is traded on NASDAQ Exchange in USA. It is located in 15 West Scenic Pointe Drive and employs 3,688 people. Healthequity is listed under Business Services category by Fama And French industry classification.

Healthequity Leadership Team

Elected by the shareholders, the Healthequity's board of directors comprises two types of representatives: Healthequity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Healthequity. The board's role is to monitor Healthequity's management team and ensure that shareholders' interests are well served. Healthequity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Healthequity's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Sydney, Executive VP of Sales and Marketing
Frode Jensen, Executive Vice President - General council and secretery
Robert Selander, Non-Executive Chairman of the Board
Evelyn Dilsaver, Independent Director
Edward Bloomberg, COO, Executive Vice President
Adrian Dillon, Director
William Otten, Executive Vice President of Sales
Larry Trittschuh, Executive Vice President Chief Security Officer
Jon Kessler, CEO and President and Director
Stephen Neeleman, Vice Chairman of the Board, Founder
Delano Ladd, Executive Vice President General Counsel and Corporate Secretary
Jon Soldan, Executive VP of Operations
Debra McCowan, Director
Frank Corvino, Independent Director
Manu Rana, Independent Director
Gary Robinson, Executive Vice President Chief Marketing Officer
Richard Putnam, IR Contact Officer
Ian Sacks, Independent Director
Angelique Hill, Executive Vice President - Operations
Michael Leavitt, Independent Director
Darcy Mott, CFO, Executive VP and Treasurer
Gayle Wellborn, Director
Jonathan Soldan, Executive Vice President - Operations
Frank Medici, Independent Director
Ashley Dreier, Executive Vice President CTO and CIO

Healthequity Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Healthequity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Healthequity without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Healthequity using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the Healthequity information on this page should be used as a complementary analysis to other Healthequity's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Healthequity Stock analysis

When running Healthequity price analysis, check to measure Healthequity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healthequity is operating at the current time. Most of Healthequity's value examination focuses on studying past and present price action to predict the probability of Healthequity's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Healthequity's price. Additionally, you may evaluate how the addition of Healthequity to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Is Healthequity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Healthequity. If investors know Healthequity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Healthequity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Healthequity is measured differently than its book value, which is the value of Healthequity that is recorded on the company's balance sheet. Investors also form their own opinion of Healthequity's value that differs from its market value or its book value, called intrinsic value, which is Healthequity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Healthequity's market value can be influenced by many factors that don't directly affect Healthequity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine Healthequity value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.